J Stroke.  2025 Jan;27(1):113-117. 10.5853/jos.2024.03062.

Thrombolysis in Patients With Versus Without Visible Occlusion: A Secondary Analysis From the AcT Trial

• Siddiqi AZ
• Ignacio K
• Kaveeta C
• Bala F
• Ademola A
• Tkach A
• Buck BH
• Catanese L
• Hunter G
• Dowlatshahi D
• Shamy M
• Zafar A
• Field TS
• Appireddy R
• Wadhwa A
• Sajobi T
• Swartz R
• Almekhlafi M
• Demchuk A
• Menon B
• Singh N

• KMID: 2564268
• DOI: http://doi.org/10.5853/jos.2024.03062

Figure

• 

  Figure 1. Hemorrhage rates and functional outcomes in patients with no visible occlusion versus those with visible occlusion. (A) Hemorrhage rates as per Heidelberg classification by visible occlusion status (yes/no). (B) Outcome by visible occlusion status (yes/no). ICH, intracranial hemorrhage; sICH, symptomatic intracerebral hemorrhage; HI1, hemorrhagic Infarction type 1; HI2, hemorrhagic Infarction type 2; PH1, parenchymal hematoma type 1; PH2, parenchymal hematoma type 2; rPH1, remote parenchymal hematoma type 1; rPH2, remote parenchymal hematoma type 2; SDH, subdural hemorrhage; SAH, subarachnoid hemorrhage; IVH, intraventricular hemorrhage; mRS, modified Rankin Scale.

Reference

References

1. Duloquin G, Graber M, Garnier L, Crespy V, Comby PO, Baptiste L, et al. Incidence of acute ischemic stroke with visible arterial occlusion: a population-based study (Dijon stroke registry). Stroke. 2020; 51:2122–2130.

2. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of arterial occlusion on outcome after intravenous thrombolysis for acute ischemic stroke. Stroke. 2015; 46:126–131.

3. Zhou Z, Delcourt C, Xia C, Yoshimura S, Carcel C, Torii-Yoshimura T, et al. Low-dose vs standard-dose alteplase in acute lacunar ischemic stroke: the ENCHANTED trial. Neurology. 2021; 96:e1512–e1526.

4. Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018. Int J Stroke. 2018; 13:949–984.

5. Sajobi T, Singh N, Almekhlafi MA, Buck B, Ademola A, Coutts SB, et al. AcT trial: protocol for a pragmatic registry-linked randomized clinical trial. Stroke Vasc Interv Neurol. 2022; 2:e000447.

6. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007; 38:1091–1096.

7. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022; 400:161–169.

8. Lahoti S, Gokhale S, Caplan L, Michel P, Samson Y, Rosso C, et al. Thrombolysis in ischemic stroke without arterial occlusion at presentation. Stroke. 2014; 45:2722–2727.

9. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol. 2003; 2:238–245.

10. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013; 44:1080–1084.